

16 October 2017

Mr Andrew Kabega
Senior Adviser, Listings Compliance
ASX Compliance Pty Ltd
20 Bridge Street, Sydney
NSW 2000

Dear Mr Kabega,

Bioxyne Limited ("BXN"): price query

We refer to your letter of 13 October 2017 and respond as follows:

1. *Is BXN aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?*
No
2. *If the answer to question 1 is "yes":*
 - a) *Is BXN relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in BXN's securities would suggest to ASX that such information may have ceased to be confidential and therefore BXN may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.*
N/A
 - b) *Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below). c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?*
N/A
3. *If the answer to question 1 is "no", is there any other explanation that BXN may have for the recent trading in its securities?*

Operationally, and as outlined in the Chairman's letter of the Annual Report, Bioxyne is progressing with the implementation of its direct sales business plan in Asia. Bioxyne has recently opened an office in Kuala Lumpur and is awaiting the formal issuance of a direct sales licence in Malaysia.

The Company continues to be active in product development and sourcing of products suitable for direct selling in Asia. As indicated in the Chairman's letter referred to above we expect direct selling operations to commence this quarter.

4. *Please confirm that BXN is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.*

Bioxyne is in compliance with the Listing Rules and particularly Listing Rule 3.1.

5. *Please confirm that BXN's responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of BXN with delegated authority from the board to respond to ASX on disclosure matters.*

Bioxyne's response to the questions above have been authorised by an officer of the Company with delegated authority from the board to respond to ASX on disclosure matters.

Guy Robertson
Company Secretary



13 October 2017

Mr Guy Robertson
Company Secretary
Bioxyne Limited
Suite 506 Level 5
50 Clarence Street
Sydney NSW 2000

By email: guy.robertson@bioxyne.com

Dear Mr Robertson,

Bioxyne Limited ("BXN"): price query

We note the change in the price of BXN's securities from a low of \$0.038 to a high of \$0.52 today, Friday, 13 October 2017.

We also note the significant increase in the volume of BXN's securities traded today on Friday, October 13, 2017.

In light of this, ASX asks BXN to respond separately to each of the following questions and requests for information:

1. Is BXN aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes":
 - a) Is BXN relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1?

Please note that the recent trading in BXN's securities would suggest to ASX that such information may have ceased to be confidential and therefore BXN may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - b) Can an announcement be made immediately?

Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that BXN may have for the recent trading in its securities?
4. Please confirm that BXN is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

5. Please confirm that BXN's responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of BXN with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by not later than half an hour before the start of trading (i.e. before 9.30 am AEDT) on Monday, 16 October 2017. If we do not have your response by then, ASX will have no choice but to consider suspending trading in BXN's securities under Listing Rule 17.3.

You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, BXN's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market.

Your response should be sent to me by e-mail at Andrew.kabega@asx.com.au. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Listing Rules 3.1 and 3.1A

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A.

In responding to this letter, you should have regard to BXN's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure: Listing Rules 3.1 – 3.1B*.

It should be noted that BXN's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in BXN's securities under Listing Rule 17.1.

If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

If you have any queries or concerns about any of the above, please contact me immediately.

Yours sincerely

[Sent electronically without signature]

Andrew Kabega
Senior Adviser, Listings Compliance (Sydney)
P: (02) 9227 0892
E: andrew.kabega@asx.com.au